Company profile
Accord BioPharma (Intas Pharmaceuticals)
Privately held: no public share price
Assets
(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
golimumab(Simponi) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseaseRheumatoid Arthritis Ulcerative Colitis |
| Approved | IL-12 p40 | Inflammatory Bowel DiseasePsoriatic Arthritis Ulcerative Colitis, Crohn's Disease |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.